Lundbeck CSO negative regarding growth hope's future in failed indication

The candidate Lu AF35700's failure against treatment-resistant schizophrenia disappoints Lundbeck as well as its shareholders, and the company's CSO gives up the candidate in this indication.

Photo: PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles